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Background. Although diosmectite has demonstrated eﬃcacy in the treatment of acute watery diarrhoea in children, its eﬃcacy
in adults still needs to be assessed. The objective of this study was therefore to assess the eﬃcacy of diosmectite on the time to
recovery in adults with acute diarrhoea. Methods. A total of 346 adults with at least three watery stools per day over a period of less
than 48 hours were prospectively randomized to diosmectite (6g tid) or placebo during four days. The primary endpoint was time
to diarrhoea recovery. Results. In the intention-to-treat population, median time to recovery was 53.8 hours (range [3.7–167.3])
with diosmectite (n = 166) versus 69.0 hours [2.2–165.2] with placebo, (n = 163; P = .029), which corresponds to a diﬀerence of
15.2 hours. Diosmectite was well tolerated. Conclusion.D i o s m e c t i t ea t6gt i dw a sw e l lt o l e r a t e da n dr e d u c e dt h et i m et or e c o v e r y
of acute watery diarrhoea episode in a clinically relevant manner.
1.Introduction
Acute diarrhoea is one of the leading causes of morbidity
worldwide [1] .T h ea n n u a lr a t eo fd i a r r h o e aa m o n ga d u l t s
in Western Europe and the United States averages about
one episode per person per year [2–4]. Episodes are usually
brief, not life-threatening and most often self-limited but
symptoms can be disturbing and incapacitating. Urgency,
loose stools, abdominal discomfort, and inconvenience such
as loss of faecal continence make it an unpleasant and
distressing condition. It is commonly recognized that these
symptoms lead to substantial costs for society as it is
estimated that half of the episodes are related to missed
workdays [5, 6].
Variousguidelinesareavailableforthetreatmentofacute
diarrhoea in adults [6–8]. Fluid intake is to be maintained,
preferably with glucose-containing drinks or electrolyte-
rich soup, as indicated by thirst. Oral rehydration solutions
are needed in frail people only. Small light meals can be
recommended, solid food intake being guided by appetite.
Several treatment options are available: antidiarrhoeal ther-
apies such as antimotility, anticholinergic, antisecretory, and
a n t i m i c r o b i a ld r u g s ,a sw e l la sa d s o r b e n t s .
Diosmectite, an activated natural aluminosilicate clay
consisting of a double aluminium and magnesium silicate,
is an adsorbent widely used for the treatment of acute
infectious diarrhoea in children. In children, diosmectite
eﬃcacy in the treatment of acute watery diarrhoea has been
assessed in a recent meta-analysis. Combined data from six
randomized, controlled trials have shown that diosmectite
signiﬁcantly reduces diarrhoea duration by one day and
increases the chance of recovery on intervention day three2 Gastroenterology Research and Practice
versuscontrolgroup[9].Tworecenttrialshaveindicatedthat
diosmectitereducesstooloutput(versusplacebo)inchildren
with acute watery diarrhoea [10].
In adults, no prospective, randomized, placebo-
controlled trial on the eﬃcacy of diosmectite in the
treatment of acute diarrhoea has yet been conducted.
Diosmectite was compared to loperamide only, in four open,
prospective trials that showed similar eﬀects for both drugs
in the treatment of acute infectious diarrhoea [11–14].
The clinical eﬀect of diosmectite has nonetheless been
studied in functional diarrhoea [15, 16], radiation-induced
diarrhoea [17], irinotecan-induced diarrhoea [18], and
AIDS-associated chronic idiopathic diarrhoea [19].
Like other adsorbents, diosmectite is not absorbed in
the intestine. It can adsorb eight times its own weight
of water, thereby diminishing free stool water. It also
adsorbs toxins, bacteria, and rotavirus, preventing their
adherence to intestinal membranes. Diosmectite strengthens
the mucosal barrier, and, in the absence of mucus, prevents
its disruption [20–22]. By consequence, on the contrary to
some antidiarrhoeal agents acting on motility, diosmectite
could decrease the time infectious agents remaining in the
intestine. However the absorbing characteristics of diosmec-
tite can disturb the absorption rates of other substances.
Therefore, the concomitant use of other medicinal products
is not recommended. Furthermore, this pharmacological
proﬁle is accompanied by a good safety proﬁle [9].
This demonstrated eﬃcacy in children suggests that,
compared to placebo, diosmectite could improve recovery
from acute watery diarrhoea in adults, but this has never
been studied. We therefore undertook a multicentre, ran-
domized, double-blind, placebo-controlled trial to assess the
eﬃcacy of diosmectite for the treatment of acute watery
diarrhoea in adults.
2.MaterialsandMethods
2.1. Patients. The study included outpatient males and
nonpregnant women aged 18 to 65 years in 23 primary and
secondary care centres in Tunisia.
Inclusion criteria were an acute diarrhoea episode
deﬁned as at least three watery stools per day over a period
of 48 hours or less, and patients with usually normal bowel
movements, that is, at least three normal stools per week and
three or less normal stools per day.
Exclusion criteria related to the diarrhoea episode were
fever >39◦C, blood or pus in stools, previous history of acute
watery diarrhoea over the past 30 days, dehydration requir-
ing intravenous rehydration, traveller’s diarrhoea, history of
chronic diarrhoea (three or more loose or watery stools per
day for at least 12 weeks, consecutive or not, in the preceding
12 months), and motor diarrhoea deﬁned as urgent, morn-
ing postprandial need for defaecation. Exclusion criteria
related to drug use were patients having used antidiarrhoeal
agents over the month prior to baseline, patients requiring
the daily intake of a drug treatment with narrow therapeutic
margin, and patients with diarrhoea possibly induced by
antibiotics, laxative agents, thyroid hormones, or colchicine.
2.2. Study Design. This was a multicentre, placebo-
controlled, double-blind, randomized study with parallel
groups conducted in 23 centres in Tunisia. Tunisia was
chosen for its good medical practice and compliant
organization and its prevalence of acute infectious diarrhoea
comparable to that of industrialized countries [4, 23].
Newly diagnosed ambulatory patients suﬀering from
acute diarrhoea presumed to be of infectious origin were
randomized to receive diosmectite or placebo. During
their participation, patients recorded in diaries their stool
frequency, presence of blood in stools, and abdominal
pain/cramps. An acute diarrhoea episode was regarded to
have resolved afterthe patient had one formed stool followed
by a nonwatery stool.
The study was registered at http://www.clinicaltrials.gov/
underthereferenceNCT00276328.Thestudywasconducted
in accordance with the declaration of Helsinki (Somerset
West, Republic of South Africa, October 1996), with the
Tunisian regulatory texts relative to the protection of persons
participating in biomedical research, and with the applicable
Good Clinical Practices requirements (USFDA 21CFR-1A
part 50 subpart D concerning children in clinical investiga-
tions; European Clinical Trials Directives 2001/20/EC and
2005/28/EC, corresponding to ICH E6). The Independent
Ethics Committee of Tunis, Tunisia, approved the study
protocol in January 2005. Patients gave their informed
consent before inclusion.
2.3. Treatment. Patients were randomly treated with either
diosmectite or placebo. Patients were randomized at visit
1, in sequential ascending order within each centre. The
investigator only dispensed the study drug to the patients
included in the study. For each study site, the sponsor-
assignedbiostatisticianpreparedalistoftreatmentallocation
codes, which were conﬁdentially supplied to the drug
supplier. The master list and the copy given to the Clinical
Trial Supplies Unit were kept conﬁdential in a safe and
securelocation.Therandomizationlistwasnotreleaseduntil
approval was received for the study to be unblinded for
analysis. For both diosmectite and placebo, treatment was
twosachetseachcontaining3gofpowderfororalsuspension
threetimesaday(morning,lunchanddinner).Fromday1to
day4,thetreatmentwasmandatory(i.e.,sixsachetsperday).
From day 5, the dose was six sachets per day until recovery,
that is, one formed stool followed by a nonwatery stool, with
a maximum of seven days of treatment.
Diosmectite is a powder for oral suspension in a sachet,
composed of 3.000g diosmectite, 0.004g vanillin, 0.007g
sodium saccharin, and 0.749g glucose monohydrate. A
placebo formula was speciﬁcally developed. It was a powder
fororal suspensionin a sachet, composed of1.000g titanium
dioxide, 1.181g maltodextrin (Roquette Glucidex IT 38),
0.004g vanillin, 0.007g sodium saccharin, 2.150g glucose
monohydrate, and 0.018g caramel colouring E150B. Placebo
was inert and identical to diosmectite in size, weight,
colour, smell, taste, and appearance, either as a powder or
a water solution. Its absence of pharmacological activity was
demonstrated on an animal model of watery diarrhoea (data
not shown). Treatment compliance was assessed at visit 2Gastroenterology Research and Practice 3
or 3, based on sachet consumption recorded in the patient
diary, overall count of used and unused sachets, and answers
to questions on study drug compliance.
2.4. Procedures. Patients attended the study centres three
times: at screening (patients included in the study began
treatment at once), at midstudy (day 4 or 5 after inclusion),
andforaconcludingexamination(day8or9afterinclusion).
At baseline visit (visit 1), written informed consent was
collected, patients were given a diary, and the following data
were collected: demographics, vital signs, weight, physical
examination results, use of concomitant medication, previ-
ous medical history, and case history of the acute diarrhoea
episode including date of ﬁrst watery stool, number of stools
over the past 24 hours, and presence of other associated
symptoms over the past 24 hours (nausea, abdominal
pain, anal irritation). Patients were asked to record the
following data every day in the diary: date, hour of stool
onset, stool consistency (watery, loose, formed, or hard),
presence of symptoms such as nausea, abdominal pain,
and anal irritation, and study drug consumption (number
of sachets taken each day). To standardize the rating of
stool consistency, patients were shown a scheme explaining
the diﬀerent stool consistencies and corresponding ratings
[24]. A stool was sampled for microbiological and parasitic
examination at baseline.
During the second and the third visits (visit 2 and visit
3), investigators collected vital signs, physical examination,
weight, adverse events, clinical data, study drug use in the
diary, stool consistency, and stool time. In addition, the
number of treatment sachets used and unused that were kept
by the investigator was recorded at visit 3.
2.5. Objectives. The primary objective was to compare
the eﬃcacy of diosmectite to that of placebo in adults
with acute watery diarrhoea, taking time to recovery as a
primaryendpoint.Thesecondaryobjectivesweretocompare
diosmectite and placebo with regards to the other eﬃcacy
parameters and safety in adults with acute watery diarrhoea.
2.6. Primary Outcome Measure. Time to recovery was
deﬁned as the time (hours) from ﬁrst study drug intake
(H0) to diarrhoea recovery. Recovery was deﬁned as the ﬁrst
formed or hard stool followed by a nonwatery stool. Time to
recovery was determined from the data collected in diaries.
However, if the diary was lost or unusable, analyses were
performed from data collected in the case report form, after
blind review decision.
2.7. Secondary Outcome Measures. Secondary eﬃcacy end-
points were time (hours) from the ﬁrst sachet intake to the
last watery stool and, per 12-hour period, number of stools,
number of watery stools, percentage of patients having
recovered (deﬁned as having achieved the primary eﬃcacy
endpoint), and percentage of patients with associated symp-
toms such as nausea, abdominal pain, and anal irritation.
2.8. Tolerability. The safety evaluation was carried out dur-
ing the follow-up visits and was based on monitoring of any
adverse event (AE) occurring from the moment patients had
given informed consent to 7 days after the end of the study.
AEs were coded according to the Medical Dictionary for
Regulatory Activities (MedDRA) version 9.1. Safety variables
were the frequency of adverse events, with a special attention
to incidence of nausea, abdominal pain, and anal irritation.
2.9. Statistics. Primary and secondary endpoints were com-
pared in both groups using appropriate statistical tests:
Wilcoxon’s test for quantitative parameters without normal
distribution described by median and range; Student’s
t-test for quantitative parameters with normal distribu-
tion described by mean and standard deviation; Mantel-
Haenszel’s test, Chi-square or Fisher’s test for qualitative
parameters described by frequency and percentage.
With regards to the primary endpoint, statistical analysis
was based on Wilcoxon’s test in the intention-to-treat
(ITT) population. The ITT population included randomized
patients having taken the study drug at least once together
with a primary endpoint that was assessable. Per-protocol
(PP) population included ITT patients without major pro-
tocol deviations as deﬁned after a blind review. PP analyses
were supportive only. To assess robustness of the results, it
was decided to perform post hoc analyses of primary eﬃcacy
data in ITT and PP populations using the “time to event”
Gehan-Wilcoxon test, which takes into account censored
dataandtheirspeciﬁcdistributionswithearlyeventsandlate
censures. Secondary eﬃcacy analyses were conducted in the
ITT population.
Sample size determination was based on the hypothesis
that time to recovery was signiﬁcantly shorter under dios-
mectite than under placebo (one-sided hypothesis). From
previous studies, the expected diﬀerence of the primary
eﬃcacy criterion between diosmectite and placebo was 24
hours, with an estimated standard deviation (SD) of 61.7
hours. With an alpha risk of 5% and a beta risk of 20%,
the number of patients to be included per group was 140 to
obtain 104 “assessable” patients per group, that is, for which
the primary outcome could be assessed.
Statistical analyses were performed using SAS (SAS
Institute, version 8.1, North Carolina, USA).
3. Results
3.1. Patient Disposition and Characteristics. Between January
2005 and July 2006, 23 physicians assessed 346 patients for
eligibility (from 1 to 52 patients per physician, mean = 15
patients per physician). A ﬂow chart of all the screened
patients (n = 346) included and randomized to receive
diosmectite (n = 173) or placebo (n = 173) is shown in
Figure 1. The total of the 346 included/randomized patients
was evaluated for safety. A total of 329 patients constituted
the ITT population. The 17 patients excluded from the
346 screened patients for ITT analysis had been invalidated
during the blinded review following an on-site audit, which
revealed that they might not have fully completed their diary.
Major protocol deviations were observed in 47 patients:
26 patients (15.7%) in the diosmectite group and 21
patients (12.9%) in the placebo group. These 47 patients4 Gastroenterology Research and Practice
Screened population
n =346
Diosmectite group
n = 173
Placebo group
n = 173
E x c l u d e df r o mI T T
population
n = 17
Placebo group
n = 10
Diosmectite group
n = 7
ITT population
n = 329
ITT: diosmectite group
n = 166
Major deviation in
placebo group
n = 21
ITT: placebo group
n = 163
Patients with at least one
major protocol deviation
n = 47
Major deviation in
diosmectite group
n = 26
PP: placebo group
n = 142
PP population
n = 282
PP:
n = 140
diosmectite group
Figure 1: Flow chart of study populations. Diosmectite (6g three times a day) or placebo in the treatment of acute diarrhoea in adults.
were excluded from ITT population to constitute the PP
population (n = 282). The most frequent deviations in
both groups were insuﬃcient stool recording in the diary
making it impossible to calculate the time to recovery (n =
39 deviations), lack of stool recording or of date/time of
recovery (n = 34), poor compliance to the treatment (n =
14), or previous or concomitant use of forbidden treatment
(n = 5). Of the 47 patients with major protocol deviation,
20 were patients that had not recovered by the end of the
study period (i.e., seven days). In contrast, another 5 of
these 47 patients had major protocol deviations due to poor
observance as a consequence of early recovery.
The two treatment groups were well balanced for
basic demographic data and disease history. There was
no diﬀerence between groups with regards to age, gender
distribution, height, and weight, previous medical history
(222/329 or 67.5% of the patients had no medical history)
and concomitant treatments. The baseline clinical picture
of acute diarrhoea episodes was not diﬀerent between both
groups (Table 1).
3.2. Primary Eﬃcacy Evaluation. In the ITT population (n =
329), the median [range] time to recovery was signiﬁcantly
shorter in the diosmectite group (53.8 hours [3.7–167.3])
than in the placebo group (69.0 hours [2.0–165.2]) when
tested with Wilcoxon’s test (P = .0294). The diﬀerence
between the two groups was 15.2 hours. The statistical
signiﬁcance of this eﬀect was also evidenced by the post
hoc analysis using the time-to-event Gehan-Wilcoxon test
considering censored data: 56.3 hours [47.7– 68.0] in the
diosmectite group versus 72.2 [63.3– 82.0] hours in the
placebo group (P = .0291).
In the PP analysis (n = 282), median time to recovery
was 54.5 hours [3.7–167.3] for the diosmectite group andGastroenterology Research and Practice 5
Table 1: Demographics, previous medical history, and characteristics of the acute diarrhoea episode.
Diosmectite Placebo
P value N = 166 N = 163
Demographics
Male, n (%) 89 (53.6) 86 (52.8) .88a
Age (years), median [range] 38.0 [19–63] 38.0 [19–66] .84b
Height, females (cm), median [range] 162.0 [150–180] 162.0 [150–182] .74b
Height, males (cm), median [range] 172.0 [158–202] 173.0 [158–189] .33b
Weight, females (kg), median [range] 64.0 [40–94] 66.0 [44–102] .29b
Weight, males (kg), median [range] 78.0 [49–107] 76.0 [55–152] .24b
Characteristics of the diarrhoea episode
Previous history of gastrointestinal disorders, n (%) 9 (5.4) 13 (8.0) .35a
Days from the 1st watery stool to inclusion, median [range] 1.0 [0–3] 1.0 [0–3] .90b
Nausea, abdominal pain, or anal irritation, n (%) 156 (94) 148 (90.8) .28a
Number of stools over the past 24 hours, median [range] 5.0 [2–22] 6.0 [3–20] .17b
Positive stool culture, n (%) 40 (29.2) 33 (22.9) .23a
Rotavirus 16 (11.9) 14 (10.0) .61a
Adenovirus 7 (5.4) 3 (2.2) .21a
Escherichia coli 13 (9.6) 13 (9.3) .92a
Staphylococcus aureus 4 (2.9) 2 (1.4) .44a
Amoebiasis 4 (2.9) 1 (0.7) .21a
a2-tailed Chi-square test; bWilcoxon’s test.
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Figure 2: Cumulative percentages of recovered patients per 12h
period.Recovery was theﬁrstformedstoolfollowed byanonwatery
stool (primary endpoint). Diosmectite (6g three times a day) or
placebo in the treatment of acute diarrhoea in adults.
68.2 hours [2.2–165.0] for the placebo group when tested
with Wilcoxon’s test (P = .067). The diﬀerence between
the median times to the end of the acute watery diarrhoea
episode was 13.7 hours. In accordance with the protocol,
the PP population excluded patients with major protocol
deviations including patients who recovered early and, as a
consequence, prematurely stopped their treatment. Five of
these patients had prematurely stopped treatment because
of a perfectly documented recovery. When including these
patients in a post hoc analysis, the Gehan-Wilcoxon time
to event test conﬁrmed the statistical signiﬁcance of the
diﬀerence, in favour of diosmectite (P = .039).
3.3. Secondary Eﬃcacy Evaluation. The percentage of ther-
apeutic success, deﬁned as patients having achieved the
primary eﬃcacy endpoint, per cumulative 12-hour period,
was higher in the diosmectite group than in the placebo
group in the following periods: 0–36h (28.5% versus 19.2%
[P = .055]); 0–48h (43.7% versus 29.5% [P = .009]); 0–
60h (52.5% versus 41.0% [P = .041]); 0–72h; 60.8% versus
50.0% [P = .055]) (Figure 2).
Median [range] time from ﬁrst sachet intake to the last
watery stool was 20.5 hours [0.0–160.8] in the diosmectite
group and 23.0 hours [0.0–223.8] in the placebo group (P =
.569). The median number of stools per 12-hour period
decreased from 3 at baseline to 1 at the 36–48h period
onwardswithasigniﬁcantdiﬀerenceinfavourofdiosmectite
group at the 72–84h period (P = .016). The median number
of watery stools decreased from 2 at baseline to 0 at the 12–
24h period onwards (N.S).
Nausea during the 24 hours before inclusion was present
in 71.7% of the patients in the diosmectite group and 68.7%
in the placebo group. Incidence decreased dramatically to
<5% in both groups after 48 hours (N.S).
Abdominal pain before inclusion was present in 86.1%
of the patients in the diosmectite group and 78.5% in the
placebo group. Incidence decreased to <15% in both groups
after 48 hours (N.S). Anal irritation before inclusion was6 Gastroenterology Research and Practice
presentin18.1%ofthepatients inthediosmectite groupand
24.5% in the placebo group. Incidence decreased to <5% in
both groups after 36 hours (N.S).
3.4. Safety and Tolerability. Both diosmectite and placebo
were well tolerated. The median [range] duration of expo-
sure was 4.2 days [0.3–7.5] in the diosmectite group and 4.2
days [0–10.1] in the placebo group. In total, 12 AEs occurred
in 11 patients during the study: 6 AEs in 6 patients (3.5%) of
the diosmectite group and 6 AEs in 5 patients (2.9%) of the
placebo group. In both groups, the most frequently reported
AEs were gastrointestinal disorders.
Particularly, incidence of new nausea episodes during the
study was observed in 4.2% (7/166) of the patients in the
diosmectite group and 3.7% (6/163) in the placebo group.
Incidence of abdominal pain episodes was observed in 2.4%
(4/166) of the patients in the diosmectite group and 8.6%
(14/163) in the placebo group. Finally, incidence of anal
irritation episodes was observed in 12.6% (21/166) of the
patients in the diosmectite group and 29.4% (48/163) in the
placebo group.
Two serious AEs were reported in two patients in the
placebo group: one case of fracture of the lower limb and
one case of appendicitis; both were assessed as unrelated to
the study drug. AEs leading to permanent study medication
discontinuation were reported in 3 patients in the diosmec-
tite group (1.7%) and in 3 patients in the placebo group
(1.7%). Gastrointestinal disorders (constipation, abdominal
pain, appendicitis, and amoebiasis) were the main reason for
discontinuation due to AEs in both groups.
During the study, no relevant abnormality was found
with regards to body weight, blood pressure, and cardiac
rhythm.
4. Discussion
This is the ﬁrst randomized, placebo-controlled trial
prospectively comparing diosmectite to placebo for the
treatment of acute diarrhoea in adults. This study showed
that oral diosmectite sachet 6g three times a day signiﬁcantly
shortened time to recovery in the treatment of acute
diarrhoeainadults.Thiswasfurthersupportedbytheresults
found in the PP population. This study also conﬁrmed the
goodsafetyproﬁleofdiosmectite,asillustratedbythelimited
number of AEs, of which only 3 were considered drug related
(constipation).
The statistical analysis plan was based upon the assump-
tion that the duration of the diarrhoea episode would
be shorter than seven days for all patients, without any
risk of data censure. It was therefore planned to compare
mean diarrhoea durations using the Wilcoxon’s test, which
is perfectly adapted to this type of data. The deﬁnition
of diarrhoea duration required that patients are followed
after the ﬁrst formed stool to conﬁrm the end of the
diarrhoea episode. This deﬁnition of recovery was selected
to guarantee the clinical relevance of the primary criterion.
Of note is that it was much more constraining than previous
trials, which deﬁned recovery as the ﬁrst nonliquid stool.
However, according to the deﬁnition of recovery used in
the study, 35 patients showed diarrhoea duration longer
than seven days. Since the protocol planned a seven-day
followup, these patients were censored in statistical analyses.
Nevertheless, a post hoc time to event analysis taking
data censure into account was carried out. The Gehan-
Wilcoxon test was preferred to the Logrank test because of
the particular distribution of the events considered and the
onset of censures during study followup. Indeed, the Gehan-
Wilcoxon test is more adapted than the Logrank test to
early events and late censures. Moreover the latter is based
upon the assumption of proportional hazards, which is most
probably not veriﬁed in this trial since the active treatment
is supposed to shorten time to recovery without modifying
the risk of recovery. Acute watery diarrhoea is self-resolving,
even in the absence of treatment. The results of the Gehan-
Wilcoxon test conﬁrmed the eﬀectiveness of diosmectite.
These results are consistent with the primary analysis and
conﬁrm that diosmectite shortens time to recovery.
Despite signiﬁcantly shorter time to recovery in the
diosmectite group, the proportions of patients achieving
recovery were similar in both groups at the end of the
study. This is explained by acute watery diarrhoea being self-
resolving within seven days.
The trial was performed in a homogeneous Tunisian
population with positive stool culture in 26% of the patients.
These ﬁgures are consistent with those reported in the
literature and previously in Tunisia [4, 6, 23, 25]. Of note
is that most patients had a recent episode of acute diarrhoea,
similar in both groups (median time from ﬁrst watery stool
to treatment onset = 1 [0–3] day from the 1st watery stool
to inclusion (NS)), with at least one associated symptom
such as nausea, abdominal pain, or anal irritation in >90%
of the patients and a median number of six stools per day
before treatment onset. Hence, it can be extrapolated that if
the primary endpoint variable had been measured from the
time of onset of diarrhoea, instead of from the ﬁrst intake
of study drug, the diﬀerence between the two groups would
still have been the same, that is, 15.2 hours. Moreover, this
pattern of diarrhoea is in accordance with the deﬁnition of
acutediarrhoeaindevelopedcountries[4,25,26].Therefore,
it can be estimated that results of the present study can be
extrapolated to western countries.
The endpoints most frequently used in trials regarding
antidiarrhoeal drugs in children and adults are stool volume
and time from treatment onset to last liquid or ﬁrst formed
stool [12, 14, 26, 27]. Except in chronic diarrhoea, trials
performed in adults rarely use stool volume as an endpoint.
Theclinicaleﬀectofdiosmectiteasanantidiarrhoealagentin
adults has been assessed mainly by the measurement of time
to transit normalization [6, 26]. The deﬁnition of recovery
chosen is again more stringent since it is based not only on
the achievement of a normal stool but also by its following a
nonwatery stool, thereby reﬂecting an actual cessation of the
acute diarrhoea episode.
The only data to which the present results may be
compared derive from trials comparing diosmectite to
loperamideinthetreatmentofacutediarrhoeainadults[11–
14]. However, heterogeneity in trial design, drug doses, and
endpoint deﬁnition makes these results diﬃcult to compareGastroenterology Research and Practice 7
with those presented here. It can only be inferred from these
studies that, depending on the modalities of treatment and
recovery deﬁnition, diosmectite and loperamide can show
similar improvements of the duration of acute diarrhoea
in adults. This is further supported by the results from the
prospective trials comparing loperamide to placebo in acute
diarrhoea in adults [27–30]. In one study the endpoint was
the mean number of stools per day [30] but in the other
three studies, the deﬁnition of time to recovery was not very
diﬀerent to that chosen here: time between the ﬁrst drug
intake and the ﬁrst 24-hour period without watery or loose
stool that was not followed by the recurrence of diarrhoea
during the following 24–48 hours. In these three trials,
median times to recovery were respectively: 45 hours 15
minutesintheplacebogroupversus23hoursand30minutes
in the 1mg loperamide group [27]; 34 hours 15 minutes in
the placebo group versus 26 hours 30 minutes in the 1mg
loperamide group [29]; 40 hours 35 minutes in the placebo
group versus 27 hours 55 minutes in the 1mg loperamide
group [28]. This corresponds to respective decreases of 21
hours, 12 hours 40 minutes, and 7 hours 45 minutes with
loperamide, which can be considered to be a similar range
to the results observed here with diosmectite. In addition,
the trial data presented here employed a more stringent
deﬁnition of recovery. In studies comparing loperamide to
placebo, time to recovery was time to the last watery stool
whereas in the present study it was time to the ﬁrst formed
or hard stool followed by a nonwatery stool.
5. Conclusions
This randomized, double-blind, placebo-controlled trial
shows that diosmectite at a dose of 6g three times a day
reduced the time to recovery of an acute watery diarrhoea
episodeinadults.Diosmectitewasalsoassociatedwithavery
good safety proﬁle and did not decrease intestinal peristalsis.
In summary, the results of the present study support the use
of diosmectite in the management of acute watery diarrhoea
in adults.
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